Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report) – Equities research analysts at B. Riley upped their FY2025 earnings estimates for shares of Tango Therapeutics in a report issued on Monday, June 9th. B. Riley analyst Y. Zhi now forecasts that the company will post earnings of ($1.37) per share for the year, up from their previous estimate of ($1.49). The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. B. Riley also issued estimates for Tango Therapeutics’ FY2026 earnings at ($1.03) EPS.
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). The firm had revenue of $5.39 million for the quarter, compared to analyst estimates of $6.73 million. Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%.
Get Our Latest Analysis on Tango Therapeutics
Tango Therapeutics Trading Down 7.1%
Shares of NASDAQ:TNGX opened at $4.69 on Thursday. The company has a 50 day moving average of $2.02 and a 200-day moving average of $2.41. The firm has a market cap of $508.37 million, a P/E ratio of -3.97 and a beta of 1.24. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $12.02.
Institutional Trading of Tango Therapeutics
Several large investors have recently added to or reduced their stakes in the business. TCG Crossover Management LLC bought a new stake in shares of Tango Therapeutics during the 4th quarter worth $33,174,000. Boxer Capital Management LLC bought a new stake in shares of Tango Therapeutics during the 4th quarter worth $32,077,000. Gilead Sciences Inc. bought a new stake in shares of Tango Therapeutics during the 4th quarter worth $15,000,000. Farallon Capital Management LLC bought a new stake in shares of Tango Therapeutics during the 4th quarter worth $12,360,000. Finally, Nantahala Capital Management LLC acquired a new position in Tango Therapeutics during the 4th quarter valued at $8,666,000. 78.99% of the stock is owned by institutional investors.
About Tango Therapeutics
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Further Reading
- Five stocks we like better than Tango Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- IBM Up 10 Days in a Row: What’s Driving the Winning Streak?
- 3 Warren Buffett Stocks to Buy Now
- Upstart Stock’s Bull Case Just Got a Lot Stronger
- How to Most Effectively Use the MarketBeat Earnings Screener
- Higher Gulf Oil Output Puts These Energy Names in Play
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.